Association of Bone Turnover Markers with Type 2 Diabetes Mellitus and Microvascular Complications: A Matched Case-Control Study

References

• Sun H, Saeedi P, Karuranga S, et al. IDF diabetes atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2022;183:109119. doi:10.1016/j.diabres.2021.109119
   PubMed Web of Science ®Google Scholar
• Tang X, Yan X, Zhou H, et al. Prevalence and identification of type 1 diabetes in Chinese adults with newly diagnosed diabetes. Diabetes Metab Syndr Obes. 2019;12:1527–1541. doi:10.2147/DMSO.S202193
   PubMed Web of Science ®Google Scholar
• World Health Organization. Diagnosis and management of type 2 diabetes (HEARTS-D); 2020. Available from: https://www.who.int/publications/i/item/who-ucn-ncd-20.1. Accessed April 17, 2023.
   Google Scholar
• Yap J, Anbalakan K, Tay WT, et al. Impact of type 2 diabetes and microvascular complications on mortality and cardiovascular outcomes in a multiethnic Asian population. BMJ Open Diabetes Res Care. 2021;9(1):e001413. doi:10.1136/bmjdrc-2020-001413
   PubMed Web of Science ®Google Scholar
• Kosiborod M, Gomes MB, Nicolucci A, et al. Vascular complications in patients with type 2 diabetes: prevalence and associated factors in 38 countries (the DISCOVER study program). Cardiovasc Diabetol. 2018;17(1):150. doi:10.1186/s12933-018-0787-8
   PubMed Web of Science ®Google Scholar
• Arnold SV, Khunti K, Tang F, et al. Incidence rates and predictors of microvascular and macrovascular complications in patients with type 2 diabetes: results from the longitudinal global discover study. Am Heart J. 2022;243:232–239. doi:10.1016/j.ahj.2021.10.181
   PubMed Web of Science ®Google Scholar
• Park S, Kang HJ, Jeon JH, Kim MJ, Lee IK. Recent advances in the pathogenesis of microvascular complications in diabetes. Arch Pharm Res. 2019;42(3):252–262. doi:10.1007/s12272-019-01130-3
   PubMed Web of Science ®Google Scholar
• Mitchell A, Fall T, Melhus H, et al. Type 2 diabetes and change in total hip bone area and bone mineral density in Swedish men and women older than 55 years. J Clin Endocrinol Metab. 2021;106(10):2840–2854. doi:10.1210/clinem/dgab490
   PubMed Web of Science ®Google Scholar
• Schousboe JT, Morin SN, Kline GA, Lix LM, Leslie WD. Differential risk of fracture attributable to type 2 diabetes mellitus according to skeletal site. Bone. 2022;154:116220. doi:10.1016/j.bone.2021.116220
   PubMed Web of Science ®Google Scholar
• Lee EJ, Jain M, Alimperti S. Bone microvasculature: stimulus for tissue function and regeneration. Tissue Eng Part B Rev. 2021;27(4):313–329. doi:10.1089/ten.TEB.2020.0154
   PubMed Web of Science ®Google Scholar
• Shanbhogue VV, Hansen S, Frost M, Brixen K, Hermann AP. Bone disease in diabetes: another manifestation of microvascular disease? Lancet Diabetes Endocrinol. 2017;5(10):827–838. doi:10.1016/S2213-8587(17)30134-1
   PubMed Web of Science ®Google Scholar
• Glendenning P, Chubb SAP, Vasikaran S. Clinical utility of bone turnover markers in the management of common metabolic bone diseases in adults. Clin Chim Acta. 2018;481:161–170. doi:10.1016/j.cca.2018.03.009
   PubMed Web of Science ®Google Scholar
• Han Y, You X, Xing W, Zhang Z, Zou W. Paracrine and endocrine actions of bone-the functions of secretory proteins from osteoblasts, osteocytes, and osteoclasts. Bone Res. 2018;6:16. doi:10.1038/s41413-018-0019-6
   PubMed Web of Science ®Google Scholar
• Shanbhogue VV, Hansen S, Frost M, et al. Compromised cortical bone compartment in type 2 diabetes mellitus patients with microvascular disease. Eur J Endocrinol. 2016;174(2):115–124. doi:10.1530/EJE-15-0860
   PubMed Web of Science ®Google Scholar
• Zwakenberg SR, van der Schouw YT, Schalkwijk CG, Spijkerman AMW, Beulens JWJ. Bone markers and cardiovascular risk in type 2 diabetes patients. Cardiovasc Diabetol. 2018;17(1):45. doi:10.1186/s12933-018-0691-2
   PubMedGoogle Scholar
• Holvik K, van Schoor NM, Eekhoff EM, et al. Plasma osteocalcin levels as a predictor of cardiovascular disease in older men and women: a population-based cohort study. Eur J Endocrinol. 2014;171(2):161–170. doi:10.1530/EJE-13-1044
   PubMed Web of Science ®Google Scholar
• Robertson CL, Ghosh G, Fitzgerald P, et al. Bone turnover markers including undercarboxylated osteocalcin are associated with mortality risk in older men. J Bone Miner Res. 2022;37(8):1464–1472. doi:10.1002/jbmr.4631
   PubMed Web of Science ®Google Scholar
• Wang J, Yan DD, Hou XH, et al. Association of bone turnover markers with glucose metabolism in Chinese population. Acta Pharmacol Sin. 2017;38(12):1611–1617. doi:10.1038/aps.2017.23
   PubMed Web of Science ®Google Scholar
• Li W, Liu X, Liu L, et al. Relationships of serum bone turnover markers with metabolic syndrome components and carotid atherosclerosis in patients with type 2 diabetes mellitus. Front Cardiovasc Med. 2022;9:824561. doi:10.3389/fcvm.2022.824561
   PubMed Web of Science ®Google Scholar
• Chinese Diabetes Society.中国2型糖尿病防治指南(2020年版) [Guideline for the prevention and treatment of type 2 diabetes mellitus in China (2020 edition)]. Chin J Diabetes Mellitus. 2021;13(4):315–409. Chinese. doi:10.3760/cma.j.cn115791-20210221-00095
   Google Scholar
• Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604–612. doi:10.7326/0003-4819-150-9-200905050-00006
   PubMed Web of Science ®Google Scholar
• Hanley AJ, Williams K, Stern MP, Haffner SM. Homeostasis model assessment of insulin resistance in relation to the incidence of cardiovascular disease: the San Antonio heart study. Diabetes Care. 2002;25(7):1177–1184. doi:10.2337/diacare.25.7.1177
   PubMed Web of Science ®Google Scholar
• Wang H, Zheng X, Zhang Y, et al. The endocrine role of bone: novel functions of bone-derived cytokines. Biochem Pharmacol. 2021;183:114308. doi:10.1016/j.bcp.2020.114308
   PubMed Web of Science ®Google Scholar
• Jung KY, Kim KM, Ku EJ, et al. Age- and sex-specific association of circulating osteocalcin with dynamic measures of glucose homeostasis. Osteoporos Int. 2016;27(3):1021–1029. doi:10.1007/s00198-015-3315-7
   PubMed Web of Science ®Google Scholar
• Hunt HB, Miller NA, Hemmerling KJ, et al. Bone tissue composition in postmenopausal women varies with glycemic control from normal glucose tolerance to type 2 diabetes mellitus. J Bone Miner Res. 2021;36(2):334–346. doi:10.1002/jbmr.4186
   PubMed Web of Science ®Google Scholar
• Mitchell A, Fall T, Melhus H, et al. Type 2 diabetes in relation to hip bone density, area, and bone turnover in Swedish men and women: a cross-sectional study. Calcif Tissue Int. 2018;103(5):501–511. doi:10.1007/s00223-018-0446-9
   PubMed Web of Science ®Google Scholar
• Dalgård C, Hansen MS, Möller S, Kyvik KO, Frost M. Disentangling the relationship between bone turnover and glucose homeostasis: a prospective, population-based twin study. Bone Rep. 2021;14:100752. doi:10.1016/j.bonr.2021.100752
   PubMedGoogle Scholar
• Salvatore T, Galiero R, Caturano A, et al. An overview of the cardiorenal protective mechanisms of SGLT2 inhibitors. Int J Mol Sci. 2022;23(7):3651. doi:10.3390/ijms23073651
   PubMed Web of Science ®Google Scholar
• Ballato E, Deepika FNU, Russo V, et al. One-year mean A1c of > 7% is associated with poor bone microarchitecture and strength in men with type 2 diabetes mellitus. Calcif Tissue Int. 2022;111(3):267–278. doi:10.1007/s00223-022-00993-x
   PubMed Web of Science ®Google Scholar
• Zhao H, Zhang M, Zhen Y, Tang Y. The relationships between glycated hemoglobin and bone turnover markers in patients with type 2 diabetes but no diabetic nephropathy. Int J Gen Med. 2022;15:5591–5598. doi:10.2147/ijgm.S366725
   PubMed Web of Science ®Google Scholar
• de la Cruz-Ares S, Cardelo MP, Gutierrez-Mariscal FM, et al. Endothelial dysfunction and advanced glycation end products in patients with newly diagnosed versus established diabetes: from the CORDIOPREV study. Nutrients. 2020;12(1):238. doi:10.3390/nu12010238
   PubMed Web of Science ®Google Scholar
• Piccoli A, Cannata F, Strollo R, et al. Sclerostin regulation, microarchitecture, and advanced glycation end-products in the bone of elderly women with type 2 diabetes. J Bone Miner Res. 2020;35(12):2415–2422. doi:10.1002/jbmr.4153
   PubMed Web of Science ®Google Scholar
• Wu Y, Xu SY, Liu SY, et al. Upregulated serum sclerostin level in the T2DM patients with femur fracture inhibits the expression of bone formation/remodeling-associated biomarkers via antagonizing Wnt signaling. Eur Rev Med Pharmacol Sci. 2017;21(3):470–478.
   PubMed Web of Science ®Google Scholar
• Sassi F, Buondonno I, Luppi C, et al. Type 2 diabetes affects bone cells precursors and bone turnover. BMC Endocr Disord. 2018;18(1):55. doi:10.1186/s12902-018-0283-x
   PubMed Web of Science ®Google Scholar
• Eckhardt BA, Rowsey JL, Thicke BS, et al. Accelerated osteocyte senescence and skeletal fragility in mice with type 2 diabetes. JCI Insight. 2020;5(9). doi:10.1172/jci.insight.135236
   PubMed Web of Science ®Google Scholar
• Peng J, Hui K, Hao C, et al. Low bone turnover and reduced angiogenesis in streptozotocin-induced osteoporotic mice. Connect Tissue Res. 2016;57(4):277–289. doi:10.3109/03008207.2016.1171858
   PubMed Web of Science ®Google Scholar
• Weng J, Chen Z, Li J, et al. Advanced glycation end products induce endothelial hyperpermeability via beta-catenin phosphorylation and subsequent up-regulation of ADAM10. J Cell Mol Med. 2021;25(16):7746–7759. doi:10.1111/jcmm.16659
   PubMed Web of Science ®Google Scholar
• Lan KC, Chiu CY, Kao CW, et al. Advanced glycation end-products induce apoptosis in pancreatic islet endothelial cells via NF-kappaB-activated cyclooxygenase-2/prostaglandin E2 up-regulation. PLoS One. 2015;10(4):e0124418. doi:10.1371/journal.pone.0124418
   PubMed Web of Science ®Google Scholar
• Hu K, Olsen BR. The roles of vascular endothelial growth factor in bone repair and regeneration. Bone. 2016;91:30–38. doi:10.1016/j.bone.2016.06.013
   PubMed Web of Science ®Google Scholar
• Lin X, Parker L, McLennan E, et al. Undercarboxylated osteocalcin improves insulin-stimulated glucose uptake in muscles of corticosterone-treated mice. J Bone Miner Res. 2019;34(8):1517–1530. doi:10.1002/jbmr.3731
   PubMed Web of Science ®Google Scholar
• Park D, Gu H, Baek JH, Baek K. Undercarboxylated osteocalcin downregulates pancreatic lipase expression in an ATF4-dependent manner in pancreatic acinar cells. Bone. 2019;127:220–227. doi:10.1016/j.bone.2019.06.009
   PubMed Web of Science ®Google Scholar
• Guo Q, Li H, Xu L, et al. Undercarboxylated osteocalcin reverts insulin resistance induced by endoplasmic reticulum stress in human umbilical vein endothelial cells. Sci Rep. 2017;7(1):46. doi:10.1016/j.bone.2019.06.009
   PubMedGoogle Scholar
• Tacey A, Smith C, Woessner MN, et al. Undercarboxylated osteocalcin is associated with vascular function in female older adults but does not influence vascular function in male rabbit carotid artery ex vivo. PLoS One. 2020;15(11):e0242774. doi:10.1371/journal.pone.0242774
   PubMed Web of Science ®Google Scholar
• Dou J, Li H, Ma X, et al. Osteocalcin attenuates high fat diet-induced impairment of endothelium-dependent relaxation through Akt/eNOS-dependent pathway. Cardiovasc Diabetol. 2014;13(1):74. doi:10.1186/1475-2840-13-74
   PubMedGoogle Scholar
• Wang C, Zhang T, Wang P, et al. Bone metabolic biomarker-based diagnosis of type 2 diabetes osteoporosis by support vector machine. Ann Transl Med. 2021;9(4):316. doi:10.21037/atm-20-3388
   PubMed Web of Science ®Google Scholar
• Ha J, Lim Y, Kim MK, et al. Comparison of the effects of various antidiabetic medication on bone mineral density in patients with type 2 diabetes mellitus. Endocrinol Metab. 2021;36(4):895–903. doi:10.3803/EnM.2021.1026
   Google Scholar
• Adil M, Khan RA, Kalam A, et al. Effect of anti-diabetic drugs on bone metabolism: evidence from preclinical and clinical studies. Pharmacol Rep. 2017;69(6):1328–1340. doi:10.1016/j.pharep.2017.05.008
   PubMed Web of Science ®Google Scholar
• Salvatore T, Galiero R, Caturano A, et al. Effects of metformin in heart failure: from pathophysiological rationale to clinical evidence. Biomolecules. 2021;11(12):1834. doi:10.3390/biom11121834
   PubMed Web of Science ®Google Scholar
• An Y, Liu S, Wang W, et al. Low serum levels of bone turnover markers are associated with the presence and severity of diabetic retinopathy in patients with type 2 diabetes mellitus. J Diabetes. 2021;13(2):111–123. doi:10.1111/1753-0407.13089
   PubMed Web of Science ®Google Scholar
• Vilaca T, Paggiosi M, Walsh JS, Selvarajah D, Eastell R. The effects of type 1 diabetes and diabetic peripheral neuropathy on the musculoskeletal system: a case-control study. J Bone Miner Res. 2021;36(6):1048–1059. doi:10.1002/jbmr.4271
   PubMed Web of Science ®Google Scholar
• Rasul S, Ilhan A, Wagner L, Luger A, Kautzky-Willer A. Diabetic polyneuropathy relates to bone metabolism and markers of bone turnover in elderly patients with type 2 diabetes: greater effects in male patients. Gend Med. 2012;9(3):187–196. doi:10.1016/j.genm.2012.03.004
   PubMedGoogle Scholar
• Kara Z, Güneş M, Bolayırlı IM, Oşar Siva Z. The effects of diabetic polyneuropathy and autonomic neuropathy on bone turnover. Metab Syndr Relat Disord. 2022;20(1):11–19. doi:10.1089/met.2021.0028
   PubMed Web of Science ®Google Scholar
• Zhu X, Zhou Y, Hong S, Xue Y, Cui Y, Rizzo R. Correlation between serum bone turnover markers and estimated glomerular filtration rate in Chinese patients with diabetes. Dis Markers. 2021;2021:6731218. doi:10.1155/2021/6731218
   PubMed Web of Science ®Google Scholar
• Maghbooli Z, Shabani P, Gorgani-Firuzjaee S, Hossein-Nezhad A. The association between bone turnover markers and microvascular complications of type 2 diabetes. J Diabetes Metab Disord. 2016;15(1):51. doi:10.1186/s40200-016-0274-2
   PubMedGoogle Scholar
• Kocak MZ, Aktas G, Duman TT, Atak BM, Savli H. Is uric acid elevation a random finding or a causative agent of diabetic nephropathy? Rev Assoc Med Bras. 2019;65(9):1155–1160. doi:10.1590/1806-9282.65.9.1156
   PubMed Web of Science ®Google Scholar
• Xing Y, Liu J, Liu H, Ma H. Relationship of bone turnover markers with serum uric acid-to-creatinine ratio in men and postmenopausal women with type 2 diabetes. Diabetes Metab Syndr Obes. 2022;15:3205–3217. doi:10.2147/dmso.S384694
   PubMed Web of Science ®Google Scholar
• Xu L, Niu M, Yu W, et al. Associations between FGF21, osteonectin and bone turnover markers in type 2 diabetic patients with albuminuria. J Diabetes Complications. 2017;31(3):583–588. doi:10.1016/j.jdiacomp.2016.11.012
   PubMed Web of Science ®Google Scholar
• Noble JH Jr. Declaration of Helsinki. Dead. BMJ. 2007;335(7623):736. doi:10.1136/bmj.39360.415833.BE
   PubMedGoogle Scholar